Axsome Therapeutics (AXSM) — AI Analysis & Mentions

Despite posting a notable Q1 net loss of $1.26/share, revenue growth (up 64% YoY to $708 million) and a surge in gross profit margin (93%) have driven investor enthusiasm, pushing the stock to an all-time high. This highlights how the market can reward high potential growth and innovation (even if profits are in the future)—but investors should be wary of overpaying for distant successes.